A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations
S2210 is reopened to Accrual, effective March 3, 2026 at 12:00 pm Pacific Standard Time.
